Latest: FDA Approves New Biosimilar for Oncology Treatment
Oncology

Oxaliplatin Elicits Improved Survival in Select Patients with Stage III CRC

by Cancer Network
0 Comments
0 Mins
Significantly improved survival was observed with oxaliplatin among patients 60 to 70 years of age with stage III CRC, but not those older than 70 years.
Tags:
Cancer Network
Author

Cancer Network

Previous Post
16 Nourishing Recipes for the End of Summer
Next Post
Artificial intelligence-guided ultrasound lacks sufficient accuracy for deep vein thrombosis detection
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago